Fractyl Health
company
About
Fractyl Health is a biotechnology company that provides curative therapies for metabolic diseases.
- 51 - 100
Details
- Last Funding Type
- Series F
- Industries
- Biotechnology,Health Care,Medical Device,Therapeutics
- Founded date
- Jan 1, 2010
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$120.76M
Fractyl Health has raised a total of
$120.76M
in funding over 2 rounds. Their latest funding was raised on
Aug 15, 2022 from a Series F round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 15, 2022 | Series F | — | 1 | — | — | Detail |
| Nov 30, 2017 | Series D | $44M | 2 | — | — | Detail |
| Nov 19, 2015 | Series C | $57M | 1 | — | — | Detail |
| Sep 4, 2014 | Series B | $19.76M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Fractyl Health is funded by 2 investors.
General Catalyst
and iDo Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
General Catalyst
|
— | Series F |
iDo Fund
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
